Evaluating the effect of intravenous immunoglubin in neonatal hemolytic jaundice caused by Rh and ABO isoimmunization
Masoumeh Hematyar1, Mehdi Zareian2
1Associate professor of “Pediatrics”, Islamic Azad University, Tehran Medical Branch
2General practitioner, Islamic Azad University, Tehran Medical Branch
History & Background: Several studies have shown that prescribing intravenous immunoglobulin(IVIG) can reduce the severity of neonatal hemolytic jaundice due to Rh and ABO incompatibility as well as the need for exchange transfusion. The present study aimed to evaluate the effect of IVIG in treatment of neonatal hemolytic jaundice caused by Rh and ABO isoimmunization.
Methods: This clinical trial study was conducted on 80 newborns with neonatal hemolytic jaundice caused by Rh and ABO isoimmunization hospitalized in the neonatal ward of Mahdieh Hospital in Tehran, Iran from 2017 to 2018. The infants were randomly assigned to case (phototherapy and IVIG) and control (phototherapy) groups. IVIG was prescribed with the dosage of 500mg/kg during 4 hours and which could be repeated for 3 doses, if required. The severity of jaundice, duration of hospitalization for phototherapy , need for exchange transfusion and IVIG complications were studied and recorded in all patients. The data were analyzed using SPSS software, Chi square and independent T-tests.
Results: In patients who received both IVIG and phototherapy, the duration of phototherapy and hospitalization as well as the need for exchange transfusion were significantly lower than the control group. No IVIG complications were observed.
Conclusion: Prescribing IVIG is an effective and safe treatment that can reduce the severity of jaundice , the need for exchange transfusion and duration of phototherapy in neonatal hemolytic jaundice due to Rh and ABO incompatibility. Cell, Gene and Therapy, Vol.1, Number 1, April 1st, 2019; 24- 28
Keywords : Neonatal jaundice, phototherapy, exchange transfusion, intravenous immunoglubin